A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study

被引:0
作者
H. Bozcuk
M. Yıldız
M. Artaç
M. Kocer
Ç. Kaya
E. Ulukal
S. Ay
M. P. Kılıç
E. H. Şimşek
P. Kılıçkaya
S. Uçar
H. S. Coskun
B. Savas
机构
[1] Akdeniz University,Department of Medical Oncology, Faculty of Medicine
[2] Antalya Training and Research Hospital,Department of Medical Oncology
[3] Necmettin Erbakan University,Department of Medical Oncology, Meram Faculty of Medicine
[4] Suleyman Demirel University,Department of Medical Oncology
来源
Supportive Care in Cancer | 2015年 / 23卷
关键词
Febrile neutropenia; Nomogram; Chemotherapy; Breast cancer; Lung cancer; Colorectal cancer;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1759 / 1767
页数:8
相关论文
共 57 条
[1]  
Herbst C(2009)Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy Cochrane Database Syst Rev 1 CD007107-2453
[2]  
Naumann F(2006)European organisation for research and treatment of cancer (EORTC) granulocyte colony-stimulating factor (G-CSF) guidelines working party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433-10
[3]  
Kruse EB(2009)Prevention of febrile neutropenia: use of granulocyte colony stimulating factors Br J Cancer 101 6-541
[4]  
Aapro MS(2010)Prophylaxis of chemotherapy induced febrile neutropenia with granulocyte colony stimulating factors: where are we know? Support Care Cancer 18 549-727
[5]  
Cameron DA(2006)Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 719-4274
[6]  
Pettengell R(2005)Randomised phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor-2 positive metastatic breast cancer administered as first line treatment. The M77001 Study Group J Clin Oncol 23 4265-3205
[7]  
Kelly S(2006)2006 update of the recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-437
[8]  
Wheatley D(2005)Risk models for chemotherapy-induced neutropenia Oncologist 10 427-374
[9]  
Aapro M(2008)Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model Am J Clin Oncol 31 369-685
[10]  
Crawford J(2009)Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European Neutropenia Study Br J Haematol 144 677-762